What is Kardigan's target valuation and expected fundraising amount in its US IPO?

Kardigan is targeting a valuation of up to $1.4 billion in its US initial public offering and aims to raise up to $373.3 million by offering 23.3 million shares priced between $14 and $16 each.

Which three late-stage experimental therapies is Kardigan advancing, and what conditions are they intended to treat?

Kardigan is advancing three late-stage experimental therapies: danicamtiv for genetic dilated cardiomyopathy, ataciguat for calcific aortic valve stenosis, and tonlamarsen for blood pressure management in acute severe hypertension—specifically targeting hepatic angiotensinogen.

Heart drug developer Kardigan targets $1.4 billion valuation in US IPO

Jun 11, 2026

Kardigan, a clinical-stage biotech focused on cardiovascular precision medicines, aims for a $1.4 billion valuation in its US IPO while raising up to $373.3 million to advance three late-stage experimental therapies.

reuters

2026-06-11

Heart drug developer Kardigan targets $1.4 billion valuation in US IPO

2026-06-18

Kardigan Surges in Nasdaq Debut After Upsized $400 Million IPO

Heart drug developer Kardigan targets $1.4 billion valuation in US IPO

FAQ